Ultime notizie per XOMA Royalty (NASDAQ:XOMA) Azioni

XOMA Royalty

XOMA

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

XOMA Royalty Corp

XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock

XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock

XOMA ROYALTY ORD

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates XOMA Royalty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) with a Buy and maintains $117 price target.

News

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on XOMA Royalty, Maintains $117 Price Target

Biotech

General

TWST

Twist Bioscience Enters Royalty Purchase Agreement With XOMA Royalty; XOMA To Provide Twist With $15M Upfront Payment In Exchange For Right To Receive Half Of Future Potential Milsetones Earned Under Antibody Discovery And Biopharma Services Collaborations

ZVRA

XOMA Royalty Says Zevra Therapeutics Received FDA Approval For MIPLYFFA; Says It Is Entitled To Receive Mid-single Digit Royalty On MIPLYFFA Sales And Up To $52.6M In Milestones

XOMA Royalty Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) ("XOMA" or the "Company") today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series B Cumulative Preferred Stock: &nbsp;
Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMAP#NASDAQ">XOMAP</a>) shall receive a cash dividend equal to $0.53906 per share.&nbsp;&nbsp;
Holders of depositary shares, each representing 1/1000 of a share of XOMA's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMAO#NASDAQ">XOMAO</a>), shall receive a cash dividend equal to $0.52344 per depositary share.&nbsp;&nbsp;
The preferred dividends will be paid on or about October 15, 2024, to respective holders of record at the close of business on October 3, 2024.&nbsp;&nbsp;

Dividends

XOMAO

XOMAP

XOMA Announces $0.53906 for Series A, $0.52344 for Series B Preferred Dividends, Record Date October 3

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains XOMA Royalty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) with a Buy and raises the price target from $74 to $117.

HC Wainwright & Co. Maintains Buy on XOMA Royalty, Raises Price Target to $117

Earnings

Earnings Beats

XOMA Q2 2024 GAAP EPS $0.84 Beats $(0.27) Estimate, Sales $11.086M Beat $8.377M Estimate

The FDA will convene a meeting with the recently formed Genetic Metabolic Diseases Advisory Committee (GeMDAC) on August 2 to review the marketing application for Zevra Therapeutics Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>) arimoclomol for Niemann-Pick <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g39687903/zevra-announces-fda-advisory-committee-meeting-to-review-arimoclomol-for-the-treatment-of-niemann-" rel="noreferrer noopener">disease type C (NPC)</a>.
The application for arimoclomol has been assigned a Prescription Drug User Fee Act (PDUFA) action date of September 21, which was <a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/g37451763/zevra-therapeutics-provides-fda-update-on-the-pdufa-action-date-for-arimoclomol-as-a-treatment-for" rel="noreferrer noopener">extended from June 21</a>.
Previously <a target="_blank" href="https://investors.zevra.com/news-releases/news-release-details/correction-kempharm-announces-corporate-name-change-zevra" rel="noreferrer noopener">known</a> as KemPharm, Zevra Therapeutics acquired&nbsp;arimoclomol from Orphazyme <a target="_blank" href="https://www.benzinga.com/general/biotech/22/05/27213663/kempharm-acquires-battered-orphazymes-arimoclomol-program-for-13m" rel="noreferrer noopener">for $12.8 million</a>.&nbsp;
In 2021, the FDA issued a complete response letter to arimoclomol as a treatment option for <a target="_blank" href="https://www.benzinga.com/general/biotech/21/06/21621339/orphazyme-wild-party-at-risk-as-fda-rejects-its-rare-neurodegenerative-disease-drug?utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+benzinga+%28Benzinga+News+Feed%29" rel="noreferrer noopener">Niemann-Pick disease type C</a>.
The CRL asked for additional qualitative and quantitative evidence to further support the validity and interpretation of the 5-domain NPC Clinical Severity Scale, <a target="_blank" href="https://www.benzinga.com/general/biotech/21/11/23783862/orphazyme-stock-gains-after-fda-update-on-arimoclomol-in-rare-neurodegenerative-disorder" rel="noreferrer noopener">particularly the swallow domain</a>.
William Blair says the data supports the efficacy and safety of arimoclomol supports approval and expects significant patient advocacy at the meeting in support of approval.
Additionally, unlike the prior filing for arimoclomol, patient groups have already sent letters of support, including a petition from the National Niemann-Pick Disease Foundation and six other NPC advocacy and research organizations with nearly 1,000 signatures from NPC patients, caregivers, and physicians.
If approved, arimoclomol would represent a significant commercial opportunity for Zevra despite the ultra-rare nature of NPC. The analyst adds that NPC is believed to affect around 900 patients in the U.S., of whom an estimated 300-400 are currently diagnosed.
The company established a commercial infrastructure for launching Olpruva earlier this year. With about 70 patients on therapy through the early access program in the U.S., the analyst expects a strong launch.
This will involve converting these patients to full-launch participants and attracting new patients, many of whom have already shown interest.
Zevra owes modest milestones and mid-single-digit royalties to XOMA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>). Given the ultra-orphan nature of the patient population, pricing will be a key variable for all stakeholders involved, pending approval.
William Blair reiterates the <a target="_blank" href="https://www.benzinga.com/quote/ZVRA/analyst-ratings" rel="noreferrer noopener">Outperform rating</a>.
Price Action: ZVRA shares are up 17.4% at $5.27 at last check Tuesday.

Analyst Color

Health Care

Movers

Trading Ideas

FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base

In the preceding three months, 5 analysts have released ratings for XOMA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $67.2, with a high estimate of $74.00 and a low estimate of $40.00. This current average represents a 9.19% decrease from the previous average price target of $74.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1720533666_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive XOMA. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$74.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$74.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$74.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Jason Zhuang</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$74.00</td>
<td>$74.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to XOMA. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of XOMA compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for XOMA's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of XOMA's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/XOMA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on XOMA analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into XOMA's Background</h2>
XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
<h3>Unraveling the Financial Story of XOMA</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Positive Revenue Trend: Examining XOMA's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 240.96% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: XOMA's net margin excels beyond industry benchmarks, reaching -668.66%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -11.66%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): XOMA's ROA stands out, surpassing industry averages. With an impressive ROA of -4.39%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: XOMA's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.47, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying XOMA: Insights From 5 Analyst Reviews

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates XOMA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) with a Buy and maintains $74 price target.

HC Wainwright & Co. Reiterates Buy on XOMA, Maintains $74 Price Target

XOMA Disclosed It Had Received An $8.1M Milestone Payment From Viracta Therapeutics, Inc., Related To Day One Biopharmaceuticals' Recent Sale Of Its Priority Review Voucher (prv) For $108MTo An Undisclosed Buyer

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on XOMA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $67.2, with a high estimate of $74.00 and a low estimate of $40.00. A decline of 9.19% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1717156840_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of XOMA's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$74.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$74.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Zhuang</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$74.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$74.00</td>
<td>$74.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to XOMA. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of XOMA compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for XOMA's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into XOMA's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/XOMA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on XOMA analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering XOMA: A Closer Look</h2>
XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
<h3>Unraveling the Financial Story of XOMA</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining XOMA's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 240.96% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -668.66%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): XOMA's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -11.66% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): XOMA's ROA stands out, surpassing industry averages. With an impressive ROA of -4.39%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 1.47, XOMA faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Peeling Back The Layers: Exploring XOMA Through Analyst Insights

XOMA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) reported quarterly losses of $(0.86) per share which missed the analyst consensus estimate of $(0.81) by 6.17 percent. This is a 12.24 percent increase over losses of $(0.98) per share from the same period last year.

Earnings Misses

XOMA Q1 2024 GAAP EPS $(0.86) Misses $(0.81) Estimate

Lexicon Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lxrx#NASDAQ">LXRX</a>) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -11.11%. A quarter ago, it was expected that this drugmaker would post a loss of $0.23 per share when it actually produced a loss of $0.20, delivering a surprise of 13.04%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Lexicon, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.13 million for the quarter ended March 2024, missing the Zacks Consensus Estimate by 3.09%. This compares to year-ago revenues of $0.02 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock&#39;s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management&#39;s commentary on the earnings call.
Lexicon shares have added about 7.8% since the beginning of the year versus the S&amp;P 500&#39;s gain of 5.2%.
What&#39;s Next for Lexicon?
While Lexicon has outperformed the market so far this year, the question that comes to investors&#39; minds is: what&#39;s next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company&#39;s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Lexicon: favorable. While the magnitude and direction of estimate revisions could change following the company&#39;s just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.16 on $2.74 million in revenues for the coming quarter and -$0.66 on $24.65 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Xoma (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xoma#NASDAQ">XOMA</a>), has yet to report results for the quarter ended March 2024.
This drug developer is expected to post quarterly loss of $0.71 per share in its upcoming report, which represents a year-over-year change of +27.6%. The consensus EPS estimate for the quarter has been revised 30.6% lower over the last 30 days to the current level.
Xoma&#39;s revenues are expected to be $0.96 million, up 117.1% from the year-ago quarter.
<a href="https://www.zacks.com/stock/news/2267479/lexicon-pharmaceuticals-lxrx-reports-q1-loss-misses-revenue-estimates?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_4-2267479">To read this article on Zacks.com click here.</a>

Penny Stocks

Small Cap

Markets

LXRX

Lexicon Pharmaceuticals Reports Q1 Loss, Misses Revenue Estimates

<ul>
<li>Organon, a global women&#39;s healthcare company, initiated XACIATO&nbsp;commercial activities in the&nbsp;fourth quarter&nbsp;of 2023.</li>
<li>XOMA further expands its late-stage portfolio with synthetic royalty and milestone interests in two additional women&#39;s health assets: Ovaprene, an investigational potential first-in-category Phase 3 hormone-free monthly intravaginal contraceptive, and Sildenafil Cream,&nbsp;3.6%, a potential first-in-category Phase 3-ready candidate for female sexual arousal disorder.</li>
<li>Bayer HealthCare holds the exclusive rights to U.S. commercialization of Ovaprene.</li>
<li>XOMA provided&nbsp;$22 million&nbsp;upfront as non-dilutive royalty capital solution to Dar&eacute; Bioscience.</li>
</ul>

DARE

Xoma Has Acquired An Economic Interest In Three Women's Health Assets From Daré Bioscience For An Upfront Payment Of $22M

4 analysts have expressed a variety of opinions on XOMA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated XOMA and provided 12-month price targets. The average target is $65.5, accompanied by a high estimate of $74.00 and a low estimate of $40.00. This current average represents a 11.49% decrease from the previous average price target of $74.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1714399219_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of XOMA by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Zhuang</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$74.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$74.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$74.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to XOMA. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of XOMA compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of XOMA's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of XOMA's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/XOMA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on XOMA analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind XOMA</h2>
XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
<h3>Financial Insights: XOMA</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: XOMA displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 23.35%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: XOMA's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1171.69% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -22.07%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): XOMA's ROA stands out, surpassing industry averages. With an impressive ROA of -11.99%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: XOMA's debt-to-equity ratio surpasses industry norms, standing at 1.4. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For XOMA

Leerink Partners analyst Jason Zhuang initiates coverage on XOMA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) with a Outperform rating and announces Price Target of $40.

Initiation

Leerink Partners Initiates Coverage On XOMA with Outperform Rating, Announces Price Target of $40

Xoma Earns $9M As FDA Grants Accelerated Approval To Day One's Ojemda (Tovorafenib) For Relapsed Or Refractory BRAF-Altered Pediatric Low-grade Glioma

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
XOMA (NASDAQ:<a href="https://investorplace.com/stock-quotes/xoma-stock-quote/">XOMA</a>) just reported results for the second quarter of 2024.<ul><li>XOMA reported earnings per share of -28 cents. This was below the analyst estimate for EPS of -27 cents.</li><li>The company reported revenue of $11.09 million.</li><li>This was 32.29% better than the analyst estimate for revenue of $8.38 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/xoma-stock-earnings-xoma-for-q2-of-2024/">XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q2 2024

In a report released today, Phil Nadeau from TD Cowen maintained a Hold rating on Xoma (XOMA – Research Report). The company's shares opened today ...

TD Cowen Keeps Their Hold Rating on Xoma (XOMA)

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Xoma (XOMA – Research Report). The associated price target was rais...

Buy Rating Affirmed: Xoma's Strategic Growth and Financial Strength Highlighted

Xoma (XOMA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wain...

Buy Rating Affirmed for XOMA on New FDA Approvals and Promising Royalty Revenue Growth

Leerink Partners analyst David Risinger has reiterated their bullish stance on XOMA stock, giving a Buy rating on September 20. David Risinger has ...

XOMA Poised for Growth: FDA Approval of Miplyffa and Strategic Acquisitions Underpin Buy Rating

I Am Banking On The Silver Tsunami With Big Dividends

XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties

XOMA Royalty Corporation (XOMA) has entered into a $15 million royalty monetization arrangement with Twist Bioscience Corporation (TWST) to acquire...

Xoma enters $15M royalty monetization arrangement with Twist Bioscience

Twist Bioscience enters into purchase agreement with XOMA Royalty

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Xoma (XOMA – Research Report). The associated price target remains ...

Comments

XOMA Royalty

Notizie

Ultime notizie per XOMA Royalty (NASDAQ:XOMA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO